An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Sponsor
Bristol-Myers Squibb
Study ID
NCT03745807
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NKTR-214 — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to assess the safety and tolerability of NTKR-214 in combination with nivolumab in Japanese participants with advanced malignant tumors.

Key Dates

Start date
Apr 9, 2019
Status verified
Sep 2021
Primary completion
Dec 18, 2019
Completion
Dec 18, 2019

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination
    NKTR-214 + nivolumab

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: Approximately 2 years ]

Related Studies